text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제64기 반기 연결재무정보 및 재무정보는 외부감사인의 검토를 받았습니다.\n1) 요약연결재무정보\n국제약품(주) 및 종속기업\xa0 \xa0\n(단위 : 원)\n구 분\n제64기 반기\n제63기\n제62기\n[유동자산]\n53,158,941,207\xa0\n49,940,201,956\xa0\n61,135,035,867\xa0\n-현금및현금성자산\n4,145,039,032\xa0\n4,013,014,774\xa0\n7,448,034,125\xa0\n-매출채권\n19,185,924,813\xa0\n20,250,681,477\xa0\n20,667,104,826\xa0\n-재고자산\n21,646,069,489\xa0\n21,651,887,423\xa0\n16,595,366,817\xa0\n-기타유동자산\n8,181,907,873\xa0\n4,024,618,282\xa0\n16,424,530,099\xa0\n[비유동자산]\n92,273,893,436\xa0\n95,685,349,934\xa0\n73,458,578,230\xa0\n-유형자산\n80,984,202,239\xa0\n84,882,176,864\xa0\n64,359,978,411\xa0\n-무형자산\n1,448,697,347\xa0\n1,492,236,263\xa0\n1,677,484,748\xa0\n-투자부동산\n3,421,672,947\xa0\n3,488,952,649\xa0\n4,093,469,130\xa0\n-기타비유동자산\n6,419,320,903\xa0\n5,821,984,158\xa0\n3,327,645,941\xa0\n자산총계\n145,432,834,643\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n[유동부채]\n54,111,814,820\xa0\n55,357,616,964\xa0\n59,250,771,507\xa0\n[비유동부채]\n20,008,107,865\xa0\n19,769,071,069\xa0\n14,388,889,463\xa0\n부채총계\n74,119,922,685\xa0\n75,126,688,033\xa0\n73,639,660,970\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,299,602,769\xa0\n29,335,099,371\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,770,814,508\xa0\n15,816,353,383\xa0\n16,683,166,546\xa0\n[이익잉여금]\n3,949,471,409\xa0\n3,058,916,238\xa0\n492,983,140\xa0\n지배기업소유주지분\n71,291,976,878\xa0\n70,482,457,184\xa0\n60,929,114,385\xa0\n비지배지분\n20,935,080\xa0\n16,406,673\xa0\n24,838,742\xa0\n자본총계\n71,312,911,958\xa0\n70,498,863,857\xa0\n60,953,953,127\xa0\n부채와자본총계\n145,432,834,643\xa0\n145,625,551,890\xa0\n134,593,614,097\xa0\n매출액\n57,010,546,992\xa0\n130,394,720,787\xa0\n111,121,601,008\xa0\n영업이익\n1,395,019,019\xa0\n6,041,374,040\xa0\n5,570,756,961\xa0\n당기순이익(손실)\n983,619,066\xa0\n2,194,568,946\xa0\n(4,761,811,946)\n\xa01.지배기업소유주지분\n979,090,659\xa0\n2,203,001,015\xa0\n(4,760,904,168)\n\xa02.비지배지분\n4,528,407\xa0\n(8,432,069)\n(907,778)\n기타포괄손익\n(124,032,090)\n7,350,341,784\xa0\n(2,384,442,638)\n당기총포괄이익(손실)\n859,586,976\xa0\n9,544,910,730\xa0\n(7,146,254,584)\n\xa01.지배기업소유주지분\n855,058,569\xa0\n9,553,342,799\xa0\n(7,145,346,806)\n\xa02.비지배지분\n4,528,407\xa0\n(8,432,069)\n(907,778)\n주당순이익(손실)\n53\xa0\n126\xa0\n(272)\n연결에 포함된 회사수\n1\xa0\n1\xa0\n1\n<종속기업 재무정보 요약>\n(2021년 반기)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,594,840\n392,533\n1,853,884\n84,908\n(2020년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,592,178\n307,625\n3,960,265\n(158,101)\n(2019년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n2) 요약재무정보\n국제약품(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n(단위 : 원)\n구 분\n제64기 반기\n제63기\n제62기\n[유동자산]\n52,592,409,712\xa0\n49,174,515,891\xa0\n60,161,878,936\xa0\n-현금및현금성자산\n4,030,172,073\xa0\n3,658,329,420\xa0\n7,218,053,324\xa0\n-매출채권\n18,843,486,861\xa0\n19,929,859,420\xa0\n20,233,344,301\xa0\n-재고자산\n21,540,333,676\xa0\n21,569,134,807\xa0\n16,296,426,007\xa0\n-기타유동자산\n8,178,417,102\xa0\n4,017,192,244\xa0\n16,414,055,304\xa0\n[비유동자산]\n91,249,264,513\xa0\n94,837,294,329\xa0\n72,940,313,200\xa0\n-유형자산\n80,491,612,395\xa0\n84,465,524,125\xa0\n64,214,202,193\xa0\n-무형자산\n1,380,448,906\xa0\n1,489,062,824\xa0\n1,674,311,309\xa0\n-투자부동산\n3,522,816,007\xa0\n3,592,170,673\xa0\n4,093,469,130\xa0\n-기타비유동자산\n5,854,387,205\xa0\n5,290,536,707\xa0\n2,958,330,568\xa0\n자산총계\n143,841,674,225\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n[유동부채]\n54,003,830,474\xa0\n55,168,831,048\xa0\n59,080,611,261\xa0\n[비유동부채]\n19,649,480,625\xa0\n19,415,080,745\xa0\n14,278,918,866\xa0\n부채총계\n73,653,311,099\xa0\n74,583,911,793\xa0\n73,359,530,127\xa0\n[자본금]\n19,276,090,000\xa0\n18,400,520,000\xa0\n18,400,520,000\xa0\n[주식발행초과금]\n2,995,998,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,189,776,043\xa0\n29,236,392,939\xa0\n21,480,876,507\xa0\n[기타자본항목]\n15,944,158,435\xa0\n15,989,697,310\xa0\n16,856,510,473\xa0\n[이익잉여금]\n2,782,340,456\xa0\n1,929,719,986\xa0\n(866,813,163)\n자본총계\n70,188,363,126\xa0\n69,427,898,427\xa0\n59,742,662,009\xa0\n자본과부채총계\n143,841,674,225\xa0\n144,011,810,220\xa0\n133,102,192,136\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n55,164,935,681\xa0\n126,514,615,485\xa0\n108,709,297,057\xa0\n영업이익\n1,305,923,105\xa0\n6,195,143,340\xa0\n5,594,782,551\xa0\n당기순이익(손실)\n941,155,958\xa0\n2,433,601,066\xa0\n(4,987,038,125)\n기타포괄손익\n(135,152,384)\n7,251,635,352\xa0\n(2,384,442,638)\n당기총포괄손익\n806,003,574\xa0\n9,685,236,418\xa0\n(7,371,480,763)\n주당순이익(손실)\n51\xa0\n139\xa0\n(285)\n']"
